Navigation Links
Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
Date:9/28/2010

nced Test, a qualitative in-vitro diagnostic test for the direct detection of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on the LightCycler® 2.0 Instrument with nasal swab specimens from patients suspected of colonization.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact: Betsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
2. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
3. Roche Launches New Initiative - Roche Goes to Town
4. Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series
5. Roche Receives FDA Clearance for U.S. Launch of cobas 8000 Modular Analyzer Series for High-Volume Laboratory Testing
6. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
7. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
8. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
9. Roche Holds Seventh Annual Childrens Walk
10. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
11. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Calif., March 24 NuRx,Pharmaceuticals, Inc. (OTC Bulletin Board: ... a Phase I clinical trial of the first-in-class,rexinoid receptor ... expects to complete in the fourth,quarter of this year, ... compound. NRX4204 is the company,s first drug candidate in ...
... March 22 Issue of The Lancet -, ... announced that efficacy results of the randomized ... the March 22 issue of The Lancet ... in,combination with 5-fluorouracil/leucovorin (5-FU/LV), a chemotherapy,regimen called ...
Cached Medicine Technology:NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5
(Date:8/27/2015)... ... August 27, 2015 , ... ... that its Krames Patient Education content is ICD-10 ready and available to all ... the new ICD-10 code sets, which are more targeted and return a more ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Analysis signed a partnership agreement for quality market research promotion on the ... by Black Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, ...
(Date:8/27/2015)... ... ... Sunbelt® Bakery, maker of delicious granola snacks that have a bakery-fresh taste with ... bars should taste with the launch of its new line of protein bars that ... , The new Protein Delights are individually wrapped wafer bars that also contain ...
(Date:8/27/2015)... Ca (PRWEB) , ... August 27, 2015 , ... ... Southern California including Los Angeles, Riverside, San Bernardino, and Orange County. ... Healthpointe’s executive physical exams are offered annually at all of its locations. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Healthpointe Now Offering Executive Physicals 2
... , , OAKLAND, ... of Medical Directors of Information Systems Award in recognition of ... The award is based on successful implementation of a technology ... practice and to improve work flow and contain health costs. ...
... WOODCLIFF LAKE, N.J., July 15 Par Pharmaceutical Companies, Inc. (NYSE: ... webcast on Tuesday, August 4, 2009 at 9:00 am EDT to review results ... financial results on August 4 before the market opens. The earnings release will ... , Access to the live webcast can be ...
... , AMSTERDAM and SAN DIEGO, July 15 Royal ... it has reached an agreement to acquire the assets of InnerCool ... involves the management of a patient,s body temperature. InnerCool, a wholly-owned ... will be acquired in an asset purchase transaction for US $11.25M, ...
... WESTFORD, Mass., July 15 Cynosure, Inc. ... of a broad array of light-based aesthetic treatment systems, today announced ... Tuesday, July 28, 2009 at 9:00 a.m. ET. , ... Officer Michael Davin and Executive Vice President and Chief Financial Officer ...
... , , , ... Inc. (NYSE: WPI ), a leading specialty pharmaceutical ... has filed an Abbreviated New Drug Application (ANDA) with the ... trospium chloride extended-release 60 mg capsules prior to the expiration ...
... , , , ... HealthLeaders-InterStudy and Fingertip Formulary find that surveyed pharmacy directors ... immune biologics will shift from a medical benefit to a ... UCB,s Cimzia among products that will be most affected by ...
Cached Medicine News:Health News:Kaiser Permanente Wins National Award for Technology-Supported Patient Care and Efficiency 2Health News:Kaiser Permanente Wins National Award for Technology-Supported Patient Care and Efficiency 3Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 2Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 3Health News:Cynosure To Announce Second-Quarter 2009 Financial Results On July 28 2Health News:Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R) 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 3
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: